Alspaugh Jonathan
SEC CIK 1868112 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc. | CFO | 165.4K | $604.7K | — | 3 | 2021-08-16 | 2022-03-11 |
Most active insiders at SYRE, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Fairmount Funds Management LLC | Dir | — | $399.66M |
| 2 | Turtle Cameron | CEO, Dir | — | $9.99M |
| 3 | HENDERSON MICHAEL THOMAS | Dir | — | $7.95M |
| 4 | Sloan Sheldon | Chief Medical Off | — | $7.35M |
| 5 | Burrows Scott L | CFO | — | $6.86M |
| 6 | King-Jones Heidy | See Remarks | — | $2.48M |
| 7 | Albers Jeffrey W. | Dir | — | $2.40M |
Alspaugh Jonathan made no open-market trades at SYRE in the last 12 months.
Transactions 3
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-15 | 2022-03-11 | SYRE | Spyre Therapeutics, Inc. | Alspaugh Jonathan | CFO | P - Purchase | $2.08 | +75.0K | 165.4K | +83% | +$156.0K | |
| 2021-12-13 | 2021-12-09 | SYRE | Spyre Therapeutics, Inc. | Alspaugh Jonathan | CFO | P - Purchase | $3.72 | +50.0K | 90.4K | +124% | +$186.0K | |
| M | 2021-08-18 | 2021-08-16+ | SYRE | Spyre Therapeutics, Inc. | Alspaugh Jonathan | CFO | P - Purchase | $6.51 | +40.4K | 9,780 | New | +$262.7K |
Purchase Sale Sale after option exercise All abbreviations